These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 27430478)

  • 1. Liquid biopsy: ready to guide therapy in advanced prostate cancer?
    Hegemann M; Stenzl A; Bedke J; Chi KN; Black PC; Todenhöfer T
    BJU Int; 2016 Dec; 118(6):855-863. PubMed ID: 27430478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
    Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN
    Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.
    Gupta S; Hovelson DH; Kemeny G; Halabi S; Foo WC; Anand M; Somarelli JA; Tomlins SA; Antonarakis ES; Luo J; Dittamore RV; George DJ; Rothwell C; Nanus DM; Armstrong AJ; Gregory SG
    Genes Chromosomes Cancer; 2020 Apr; 59(4):225-239. PubMed ID: 31705765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Application of Liquid Biopsies in Metastatic Prostate Cancer.
    Morrison GJ; Goldkorn A
    Curr Oncol Rep; 2018 Mar; 20(4):35. PubMed ID: 29572775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
    Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
    Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of emerging liquid biomarkers in advanced prostate cancer.
    Vandekerkhove G; Chi KN; Wyatt AW
    Cancer Genet; 2018 Dec; 228-229():151-158. PubMed ID: 28958406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using circulating cell-free DNA to monitor personalized cancer therapy.
    Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
    Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer.
    Amato RJ; Melnikova V; Zhang Y; Liu W; Saxena S; Shah PK; Jensen BT; Torres KE; Davis DW
    Urology; 2013 Jun; 81(6):1303-7. PubMed ID: 23622774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer.
    Soekmadji C; Corcoran NM; Oleinikova I; Jovanovic L; ; Ramm GA; Nelson CC; Jenster G; Russell PJ
    Prostate; 2017 Oct; 77(14):1416-1423. PubMed ID: 28856701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.
    Earl J; Garcia-Nieto S; Martinez-Avila JC; Montans J; Sanjuanbenito A; Rodríguez-Garrote M; Lisa E; Mendía E; Lobo E; Malats N; Carrato A; Guillen-Ponce C
    BMC Cancer; 2015 Oct; 15():797. PubMed ID: 26498594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in circulating tumor cells and cell-free DNA in metastatic prostate cancer: a review.
    Parimi S; Ko JJ
    Expert Rev Anticancer Ther; 2017 Oct; 17(10):939-949. PubMed ID: 28737470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer.
    Gourdin T; Sonpavde G
    Asian J Androl; 2018; 20(3):230-237. PubMed ID: 29578115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiparametric liquid biopsy analysis in metastatic prostate cancer.
    Hodara E; Morrison G; Cunha A; Zainfeld D; Xu T; Xu Y; Dempsey PW; Pagano PC; Bischoff F; Khurana A; Koo S; Ting M; Cotter PD; Moore MW; Gunn S; Usher J; Rabizadeh S; Danenberg P; Danenberg K; Carpten J; Dorff T; Quinn D; Goldkorn A
    JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30702443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors.
    Goodman OB; Fink LM; Symanowski JT; Wong B; Grobaski B; Pomerantz D; Ma Y; Ward DC; Vogelzang NJ
    Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1904-13. PubMed ID: 19505924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microfluidic enrichment of circulating tumor cells in patients with clinically localized prostate cancer.
    Todenhöfer T; Park ES; Duffy S; Deng X; Jin C; Abdi H; Ma H; Black PC
    Urol Oncol; 2016 Nov; 34(11):483.e9-483.e16. PubMed ID: 27658563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.
    Adams DL; Stefansson S; Haudenschild C; Martin SS; Charpentier M; Chumsri S; Cristofanilli M; Tang CM; Alpaugh RK
    Cytometry A; 2015 Feb; 87(2):137-44. PubMed ID: 25515318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
    Punnoose EA; Atwal S; Liu W; Raja R; Fine BM; Hughes BG; Hicks RJ; Hampton GM; Amler LC; Pirzkall A; Lackner MR
    Clin Cancer Res; 2012 Apr; 18(8):2391-401. PubMed ID: 22492982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer.
    Daniel M; Knutson TP; Sperger JM; Li Y; Singh A; Stahlfeld CN; Passow C; Auch B; Lang JM; Dehm SM
    Endocr Relat Cancer; 2021 Aug; 28(9):645-655. PubMed ID: 34280123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation.
    Lowes LE; Bratman SV; Dittamore R; Done S; Kelley SO; Mai S; Morin RD; Wyatt AW; Allan AL
    Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27618023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor cells in breast cancer: functional heterogeneity, pathogenetic and clinical aspects.
    Cherdyntseva NV; Litviakov NV; Denisov EV; Gervas PA; Cherdyntsev ES
    Exp Oncol; 2017 Mar; 39(1):2-11. PubMed ID: 28361862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.